Over five years ago, a small group of luminaries in the prostate cancer (PCa) world issued a critique of rising PSA as a trigger for prostate cancer intervention when patients are on active surveillance (AS).[i] The co-authors include Patrick Walsh (father of the nerve-sparing prostatectomy), Alan Partin (credited with inventing the PSA blood test), Jonathan keep reading
Androgen deprivation therapy (ADT) is a treatment for prostate cancer that has spread outside the gland. It is also called hormone therapy or chemical castration. The purpose of ADT is to reduce the production of male hormones, especially testosterone, which has the effect of temporarily halting the ability of prostate cancer cells to multiply and keep reading
Dr. Peter Pinto is one of the most respected urologic researchers in America. He is the Head of the Prostate Cancer Section of the Urologic Oncology Branch of the Center for Cancer Research (National Cancer Institute/National Institutes of Health). That’s a very long formal title for a man who is humble, personable and good-natured. His keep reading
The University of California/Los Angeles (UCLA) completed a study that not only affirms our work at the Sperling Prostate Center but also offers terrific news for all prostate cancer patients. A team from their medical school’s Department of Radiology completed a retrospective study of in-bore MRI-guided prostate biopsy cases. They found that in-bore biopsy is keep reading
I read a study on the accuracy of prostate MRI for predicting that no prostate cancer (PCa) is present. This is called the negative predictive value (NPV), and the authors make a great point in their introduction: The reliability of a negative MRI is a key clinical metric – if the MRI is reported as keep reading
The number of prostate cancer patients who opt for active surveillance (AS) is rising. The most important reason men go on AS is to avoid the risks that accompany whole-gland treatments. In fact, it’s so important to patients that according to a Dutch study, 30% who were not considered candidates for AS chose it anyway keep reading
When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading
An update on COVID-19: Your health and safety are our top priority.